ClinicalTrials.gg
CompletedNCT04564027Updated Aug 29, 2025Results posted

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

A Phase 2 interventional study of Ceralasertib in Advanced Solid Tumours, sponsored by AstraZeneca. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations

Read the detailed description

Current module of the study will consist of 2 cohorts as follows:

Cohort A (Advanced Solid Tumours [AST]): A total of \~25 molecularly eligible and centrally confirmed participants dosed at ceralasertib 160 mg twice daily will be enrolled into this cohort.

Cohort B (Metastatic castration-resistant prostate cancer [mCRPC]): A total of \~27 molecularly eligible and centrally confirmed participants dosed at ceralasertib 160 mg twice daily will be enrolled into Cohort B. Unfavourable circulating tumour cells (CTC) count requirement may be introduced for all participants to ensure an adequate (approximately ≥ 50%) number of participants with CTC count ≥ 5/7.5 mL blood.

The screening will have 2 parts, Part 1 and Part 2, which apply for both Cohort A and Cohort B.

02

Conditions studied

  • Advanced Solid Tumours

Keywords

  • Ataxia telangiectasia mutated
  • Metastatic castration-resistant prostate cancer
  • Rad3-related protein
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of (excluding NSCLC) or mCRPC tumour.
  • Participants must have a deleterious or suspected deleterious ATM mutation in tumour or blood (germline or ctDNA). Definitions of qualifying ATM mutations may include deleterious/suspected deleterious, pathogenic/likely pathogenic, disease- or cancer-associated variants, or equivalent wording. Variants of unknown significance, benign or likely benign alterations are not qualifying.
  • Participant must have normal organ and bone marrow function measured within 28 days prior to the first dose of study intervention.
  • Participants who have no curative treatment options and are deemed appropriate for an study in the opinion of the investigator.
  • Availability of archival or fresh tumour specimens for central testing of ATM protein loss using immunohistochemistry and for confirmation of ATM mutation using next generation sequencing.
  • Previously received and progressed on at least one novel hormonal agent (eg, abiraterone acetate, apalutamide, and/or enzalutamide) for the treatment of prostate cancer
  • Participants with histologically confirmed castrate resistant prostate cancer.
  • Documented prostate cancer progression at study entry while on androgen deprivation or after bilateral orchiectomy as assessed by the investigator.
  • Serum testosterone levels ≤ 50 ng/dL (≤ 1.75 nmol/L) within (≤) 28 days before enrolment.

Exclusion criteria

Exclusion Criteria:

  • Any of the following cardiac diseases currently or within the last 6 months:

    1. Unstable angina pectoris.
    2. Congestive heart failure > Class 2 as defined by the
    3. Acute myocardial infarction.
    4. Significant ventricular or supraventricular arrhythmias.
    5. Mean resting interval (QTc) > 470 msec obtained from three (ECGs) in 24 hours using the Fredericia formula.
    6. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, immediate family history of long QT syndrome or unexplained sudden death under 40 years of age.
    7. For Cohort B (mCRPC]), surgery or local prostatic intervention (excluding a prostatic ) within 28 days of Cycle 1 Day 1.
  • Participants with known active infections ((i.e., or C, tuberculosis, or COVID-19).
  • Participants considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection.
  • Participants with symptomatic and/or uncontrolled .
  • Previous therapy with an telangiectasia and rad3 related protein inhibitor.
  • Exposure to a small molecule product within 14 days or 5 half-lives.
  • Concomitant use of known strong CYP 3A inhibitors and inducers.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cohort A

    Eligible participants (ATM altered AST), will receive oral dose of Ceralasertib as monotherapy.

    Drug: Ceralasertib

  • Experimental
    Cohort B

    Eligible participants (ATM altered mCRPC), will receive oral dose of Ceralasertib as monotherapy.

    Drug: Ceralasertib

Interventions

  • Tablets will be administered orally

    Also known as: AZD6738

06

What researchers measure

Primary outcomes

  1. Cohort A (aST): Objective Response Rate (ORR).

    ORR is defined as the percentage of participants who have at least one response of complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by response evaluation criteria in solid tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

    Time frame: 2 years 4 months

  2. Cohort B (mCRPC): Composite Response Rate.

    Composite response rate is defined as the investigator assessed radiological response by RECIST 1.1 for soft tissue and visceral lesions and Prostate Cancer Working Group 3 (PCWG3) for bone lesions, confirmed prostate specific antigen (PSA) decline of more than 50%, and/or confirmed circulating tumour cell \[CTC\] conversion from unfavorable (\>=5 cells/7.5 ml blood) to favorable (\<5 cells). Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

    Time frame: Up to 2 years 4 months

Secondary outcomes

  1. Cohort A (aST): Duration of Radiological Response (DoR)

    DoR is defined as the time from the date of first documented response (confirmed CR/PR) until date of documented progression or death in the absence of disease progression.

    Time frame: Up to 2 years 4 months

  2. Cohort A (aST): Progression Free Survival (PFS)

    PFS is defined as the time from start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression. Progression is defined using (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

    Time frame: Up to 2 years 4 months

  3. Cohort A (aST): Percentage Change in Tumor Size

    Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size.

    Time frame: Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32), 5 (Week 40), 6 (Week (48), 7 (Week 56)

  4. Cohort B (mRCPC): Percentage Change in Tumor Size

    Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

    Time frame: Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32)

  5. Cohort A (aST) and B (mCRPC): Number of Participants With Serious and Non-serious Adverse Events

    The adverse events as a variable of safety and tolerability after admiration of ceralasertib was determined.

    Time frame: From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose), up to 2 years 4 months

07

Results

Posted Jun 25, 2024

Participant flow

Participants were enrolled in this study from 01 December 2020 to 04 April 2023 at 18 centers in 3 countries.

Participant flow — Overall Study
MilestoneCohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of Ceralasertib
Started830115
Completed827115
Not completed0300
Withdrew: Ongoing treatment at data cut off0300

Outcome measures

PrimaryCohort A (aST): Objective Response Rate (ORR).

ORR is defined as the percentage of participants who have at least one response of complete response (CR) or partial response (PR) prior to any evidence of progression (as defined by response evaluation criteria in solid tumours \[RECIST\] 1.1) that is confirmed at least 4 weeks later. The CR is defined as disappearance of all target and non-target lesions and no new lesions. The PR is defined as \>= 30% decrease in the sum of the diameters of target lesions compared to baseline and no new non-target lesion. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

Time frame:
2 years 4 months
Reported as:
Number · Percentage of participants
Cohort A (aST): Objective Response Rate (ORR).
Percentage of participantsCohort A (aST): 160 mg of Ceralasertib
Cohort A (aST): Objective Response Rate (ORR).7.14 (1.9 to 17.9)
PrimaryCohort B (mCRPC): Composite Response Rate.

Composite response rate is defined as the investigator assessed radiological response by RECIST 1.1 for soft tissue and visceral lesions and Prostate Cancer Working Group 3 (PCWG3) for bone lesions, confirmed prostate specific antigen (PSA) decline of more than 50%, and/or confirmed circulating tumour cell \[CTC\] conversion from unfavorable (\>=5 cells/7.5 ml blood) to favorable (\<5 cells). Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

Time frame:
Up to 2 years 4 months
Reported as:
Number · Percentage of participants
Cohort B (mCRPC): Composite Response Rate.
Percentage of participantsCohort B (mCRPC): 160 mg of Ceralasertib
Cohort B (mCRPC): Composite Response Rate.7.7 (0.8 to 26.8)
SecondaryCohort A (aST): Duration of Radiological Response (DoR)

DoR is defined as the time from the date of first documented response (confirmed CR/PR) until date of documented progression or death in the absence of disease progression.

Time frame:
Up to 2 years 4 months

No measurements were reported for this outcome.

SecondaryCohort A (aST): Progression Free Survival (PFS)

PFS is defined as the time from start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy prior to progression. Progression is defined using (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

Time frame:
Up to 2 years 4 months
Reported as:
Median · Months
Cohort A (aST): Progression Free Survival (PFS)
MonthsCohort A (aST): 160 mg of Ceralasertib
Cohort A (aST): Progression Free Survival (PFS)3.7 (1.9 to 5.6)
SecondaryCohort A (aST): Percentage Change in Tumor Size

Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size.

Time frame:
Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32), 5 (Week 40), 6 (Week (48), 7 (Week 56)
Reported as:
Mean · Percentage change
Cohort A (aST): Percentage Change in Tumor Size
Percentage changeCohort A (aST): 160 mg of CeralasertibCohort A (aST): 240 mg of Ceralasertib
Scan Visit 1 (Week 8)6.6 ± 22.456.2 ± 10.99
Scan Visit 2 (Week 16)-4.7 ± 16.835.4 ± NA
Scan Visit 3 (Week 24)-12.8 ± 21.47—
Scan Visit 4 (Week 32)-17.9 ± 34.41—
Scan Visit 5 (Week 40)-1.1 ± NA—
Scan Visit 6 (Week 48)-100 ± NA—
Scan Visit 7 (Week 56)-100 ± NA—
SecondaryCohort B (mRCPC): Percentage Change in Tumor Size

Percentage change in tumour size is defined as the reduction from baseline or the increase from baseline in the absence of a reduction in the sum of the longest diameters (or the short axis measurements for lymph nodes) of the target lesions. A negative change denotes a reduction in target lesion size. Due to an increased frequency and early onset of Grade≥3 hematological toxicity noted among the participants receiving 240 mg of Ceralsertib, the sponsor decreased the dose to 160mg. Therefore, patients with the 240 mg BID starting dose were not included in the efficacy analyses for both study cohorts.

Time frame:
Scan Visits 1 (Week 8), 2 (Week 16), 3 (Week 24), 4 (Week 32)
Reported as:
Mean · Percentage change
Cohort B (mRCPC): Percentage Change in Tumor Size
Percentage changeCohort B (mCRPC): 160 mg of Ceralasertib
Scan Visit 1 (Week 8)2.0 ± 21.35
Scan Visit 2 (Week 16)-6.0 ± 9.37
Scan Visit 3 (Week 24)-1.4 ± 11.75
Scan Visit 4 (Week 32)-5.2 ± 13.21
SecondaryCohort A (aST) and B (mCRPC): Number of Participants With Serious and Non-serious Adverse Events

The adverse events as a variable of safety and tolerability after admiration of ceralasertib was determined.

Time frame:
From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose), up to 2 years 4 months
Reported as:
Count of participants · Participants
Cohort A (aST) and B (mCRPC): Number of Participants With Serious and Non-serious Adverse Events
ParticipantsCohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of Ceralasertib
All Adverse events (AE)830115
Any AE possibly related to treatment821113
Any AE of CTCAE Grade 3 or higher61518
Any AE of CTCAE Grade 3 or higher, possibly related to IP4615
Any AE with outcome of death0010
Any AE with outcome = death, possibly related to IP0010
Any SAE (including events with outcome = death)6414
Any SAE (including events with outcome = death), possibly related to IP3211
Any SAE leading to discontinuation of IP0110
Any SAE leading to discontinuation of IP, possibly related to IP0010
Any AE leading to discontinuation of IP0111
Any AE leading to discontinuation of IP, possibly related to IP0011
Any AE leading to dose modification41015
Any AE leading to dose reduction1403
Any AE leading to dose interruption4713
Any AE leading to dosing cycle delays1001
Any other significant AEs0000

Adverse events

Collected over From Screening (Day -28 to Day -1) Until Follow-up (30 days post last dose), up to 2 years 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (aST): 240 mg of Ceralasertib0/8 (0%)6/8 (75%)8/8 (100%)
Cohort A (aST): 160 mg of Ceralasertib0/30 (0%)4/30 (13.3%)30/30 (100%)
Cohort B (mCRPC): 240 mg of Ceralasertib1/1 (100%)1/1 (100%)1/1 (100%)
Cohort B (mCRPC): 160 mg of Ceralasertib0/15 (0%)4/15 (26.7%)15/15 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventCohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of Ceralasertib
Cardiac arrestCardiac disorders0/80/301/10/15
DiarrhoeaGastrointestinal disorders0/81/301/10/15
Platelet count decreasedInvestigations2/80/300/10/15
SepsisInfections and infestations1/80/300/10/15
Febrile neutropeniaBlood and lymphatic system disorders1/80/300/10/15
ThrombocytopeniaBlood and lymphatic system disorders1/80/300/10/15
Confusional statePsychiatric disorders1/80/300/10/15
HypoxiaRespiratory, thoracic and mediastinal disorders1/80/300/10/15
Pleural effusionRespiratory, thoracic and mediastinal disorders1/80/300/10/15
Small intestinal obstructionGastrointestinal disorders1/80/300/10/15
Most frequent other events
Showing 10 of 105
Most frequent other events
EventCohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of Ceralasertib
LeukopeniaBlood and lymphatic system disorders0/80/301/11/15
NeutropeniaBlood and lymphatic system disorders0/80/301/12/15
Decreased appetiteMetabolism and nutrition disorders2/86/301/13/15
DehydrationMetabolism and nutrition disorders1/81/301/10/15
AnxietyPsychiatric disorders1/81/301/10/15
DepressionPsychiatric disorders0/80/301/10/15
CoughRespiratory, thoracic and mediastinal disorders2/83/301/10/15
DyspnoeaRespiratory, thoracic and mediastinal disorders4/84/301/12/15
DiarrhoeaGastrointestinal disorders1/85/301/10/15
Platelet count decreasedInvestigations2/82/301/11/15

Baseline characteristics

Safety analysis set consists of all participants who received at least 1 dose of study intervention.

Age, Customized
Age, Customized(Participants)Cohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of CeralasertibTotal
18-64 years3110317
65-84 years51911237
≥ 85 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of CeralasertibTotal
Female5140019
Male31611535
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of CeralasertibTotal
Black or African American00000
Native Hawaiin or Other Pacific Islander00000
White8110625
Not Reported070411
Missing090514
Other03104
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A (aST): 240 mg of CeralasertibCohort A (aST): 160 mg of CeralasertibCohort B (mCRPC): 240 mg of CeralasertibCohort B (mCRPC): 160 mg of CeralasertibTotal
Hispanic or Latino03014
Not Hispanic or Latino8131931
Missing0140519
08

Study locations

18 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Los Angeles, California 90089, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Indianapolis, Indiana 46202, United States
  • Research Site
    Baltimore, Maryland 21231, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Las Vegas, Nevada 89119, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Ephrata, Pennsylvania 17522, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Myrtle Beach, South Carolina 29572, United States
  • Research Site
    Bordeaux, 33076, France
  • Research Site
    Dijon, 21079, France
  • Research Site
    Lyon, 69373, France
  • Research Site
    Vandœuvre-lès-Nancy, 54519, France
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28050, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the requests portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Feb 2025, 50 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 25, 2020
StartActual
Dec 1, 2020
Primary completionActual
Feb 18, 2025
CompletionActual
Feb 18, 2025
Results first posted
Jun 25, 2024
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04564027
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Dec 1, 2020
Primary completion
Feb 18, 2025
Completion
Feb 18, 2025
Results posted
Jun 25, 2024
Last update
Aug 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceralasertib

Start the discussion